$VIRX
Viracta Therapeutics, Inc.

2013 Q4 Form 10-K Financial Statement

#000119312514086649 Filed on March 06, 2014

View on sec.gov

Income Statement

Concept 2013 Q4 2013 2012 Q4
Revenue $1.989M $7.956M $1.989M
YoY Change 0.0% 111.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.700M $10.84M $2.470M
YoY Change 9.31% 18.08% 14.35%
% of Gross Profit
Research & Development $6.880M $28.89M $7.590M
YoY Change -9.35% -1.01% 19.91%
% of Gross Profit
Depreciation & Amortization $0.00 $20.00K $10.00K
YoY Change -100.0% -35.48% 0.0%
% of Gross Profit
Operating Expenses $9.580M $39.73M $10.06M
YoY Change -4.77% 3.57% 18.49%
Operating Profit -$31.77M
YoY Change -8.19%
Interest Expense -$620.0K $2.917M -$840.0K
YoY Change -26.19% 57.25% 223.08%
% of Operating Profit
Other Income/Expense, Net $1.040M $92.00K $4.860M
YoY Change -78.6% -101.23%
Pretax Income -$7.180M -$34.60M -$4.050M
YoY Change 77.28% -21.28% -53.66%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.180M -$34.60M -$4.050M
YoY Change 77.28% -21.28% -53.66%
Net Earnings / Revenue -360.99% -434.87% -203.62%
Basic Earnings Per Share -$0.13 -$0.66 -$0.08
Diluted Earnings Per Share -$0.15 -$0.66 -$0.20
COMMON SHARES
Basic Shares Outstanding 54.06M shares 52.25M 51.41M shares
Diluted Shares Outstanding 55.57M shares 52.25M 52.85M shares

Balance Sheet

Concept 2013 Q4 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.30M $39.29M $71.20M
YoY Change -44.8% -44.84% 61.45%
Cash & Equivalents $15.12M $15.12M $14.94M
Short-Term Investments $24.20M $24.17M $56.30M
Other Short-Term Assets $1.200M $1.200M $1.700M
YoY Change -29.41% -29.82% 6.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.49M $40.49M $72.93M
YoY Change -44.48% -44.48% 59.71%
LONG-TERM ASSETS
Property, Plant & Equipment $23.00K $20.00K $43.00K
YoY Change -46.51% -50.0% -41.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $42.00K
YoY Change -76.19% -75.0% -67.69%
Total Long-Term Assets $33.00K $40.00K $85.00K
YoY Change -61.18% -55.56% -58.33%
TOTAL ASSETS
Total Short-Term Assets $40.49M $40.49M $72.93M
Total Long-Term Assets $33.00K $40.00K $85.00K
Total Assets $40.53M $40.53M $73.02M
YoY Change -44.5% -44.49% 59.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $953.0K $950.0K $78.00K
YoY Change 1121.79% 1087.5% -88.15%
Accrued Expenses $8.100M $8.110M $9.000M
YoY Change -10.0% -10.19% 66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.000M $9.020M $6.600M
YoY Change 36.36% 36.46%
Total Short-Term Liabilities $33.97M $33.97M $31.74M
YoY Change 7.03% 7.03% 278.64%
LONG-TERM LIABILITIES
Long-Term Debt $9.000M $9.030M $17.70M
YoY Change -49.15% -48.84% 86.32%
Other Long-Term Liabilities $3.700M $3.710M $11.70M
YoY Change -68.38% -68.21%
Total Long-Term Liabilities $12.70M $12.74M $29.40M
YoY Change -56.8% -56.55% 209.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.97M $33.97M $31.74M
Total Long-Term Liabilities $12.70M $12.74M $29.40M
Total Liabilities $46.70M $46.71M $61.10M
YoY Change -23.57% -23.5% 243.26%
SHAREHOLDERS EQUITY
Retained Earnings -$479.7M -$445.1M
YoY Change 7.77% 10.96%
Common Stock $473.5M $457.0M
YoY Change 3.61% 6.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.184M -$6.180M $11.96M
YoY Change
Total Liabilities & Shareholders Equity $40.53M $40.53M $73.02M
YoY Change -44.5% -44.49% 59.19%

Cashflow Statement

Concept 2013 Q4 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$7.180M -$34.60M -$4.050M
YoY Change 77.28% -21.28% -53.66%
Depreciation, Depletion And Amortization $0.00 $20.00K $10.00K
YoY Change -100.0% -35.48% 0.0%
Cash From Operating Activities -$9.700M -$37.42M -$9.260M
YoY Change 4.75% 251.65% 27.37%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$450.0K $32.22M -$21.19M
YoY Change -97.88% -250.77% 322.95%
Cash From Investing Activities -$450.0K $32.22M -$21.19M
YoY Change -97.88% -250.75% 323.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.540M 5.388M 3.760M
YoY Change -5.85% -85.69% -61.2%
NET CHANGE
Cash From Operating Activities -9.700M -37.42M -9.260M
Cash From Investing Activities -450.0K 32.22M -21.19M
Cash From Financing Activities 3.540M 5.388M 3.760M
Net Change In Cash -6.610M 181.0K -26.69M
YoY Change -75.23% -96.78% 934.5%
FREE CASH FLOW
Cash From Operating Activities -$9.700M -$37.42M -$9.260M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$9.700M -$37.42M -$9.260M
YoY Change 4.75% 251.65% 27.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Public Float
EntityPublicFloat
161231319
CY2010Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3678798 shares
CY2010Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7357610 shares
CY2010Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.52
CY2011Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60094843 shares
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
42247000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14223000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
28020000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9311000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51565000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51565000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.14
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6288000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.52
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2113000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
78000
CY2012Q4 us-gaap Notes Payable Current
NotesPayableCurrent
6610000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
243000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
136383000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31741000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
38000
CY2012Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8070000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1465000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11957000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457011000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-445097000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7956000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73017000
CY2012Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
17651000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11668000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
56287000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
72932000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
70646000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2281000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
110791000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
136383000
CY2012Q4 us-gaap Assets
Assets
73017000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14940000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
194000
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
146000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10586000
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7850000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
70684000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1705000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43000
CY2012Q4 snss Cash Equivalents Gross Unrealized Gains
CashEquivalentsGrossUnrealizedGains
CY2012Q4 snss Common Stock Fair Value
CommonStockFairValue
4.20
CY2012Q4 snss Cash Equivalents Estimated Fair Value
CashEquivalentsEstimatedFairValue
14397000
CY2012Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
2.59
CY2012Q4 snss Cash Equivalents Gross Unrealized Losses
CashEquivalentsGrossUnrealizedLosses
CY2012Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
4535000
CY2012Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
5449000
CY2012Q4 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
14397000
CY2012Q4 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
3118000 shares
CY2012Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
44000
CY2012Q4 snss Other Accruals Current
OtherAccrualsCurrent
275000
CY2012Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
6000
CY2012Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
1595000
CY2012Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
56249000
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7931000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1719000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-6184000
CY2012Q4 snss Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
6000
CY2012Q4 snss Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
44000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54344000 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9978000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54344000 shares
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19891000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.61
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7611000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2302000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.60
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7339000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.80
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4193000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.52
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1645000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
48000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
953000
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
9018000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
149027000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33972000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473509000
CY2013Q4 us-gaap Notes Payable
NotesPayable
18043000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-479695000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7956000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40525000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9025000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3712000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
4500000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
48000
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24172000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
40492000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30758000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3212000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
123490000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
149027000
CY2013Q4 us-gaap Assets
Assets
40525000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14378000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15121000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
341000
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
133000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
13559000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12064000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9281000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4668000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30755000
CY2013Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39300000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1199000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14624000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7800000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2013Q4 snss Cash Equivalents Gross Unrealized Gains
CashEquivalentsGrossUnrealizedGains
CY2013Q4 snss Operating Leases Future Minimum Payments Including Effect Of Lease Extension Executed Due Current
OperatingLeasesFutureMinimumPaymentsIncludingEffectOfLeaseExtensionExecutedDueCurrent
332000
CY2013Q4 snss Common Stock Fair Value
CommonStockFairValue
4.74
CY2013Q4 snss Share Based Compensation Arrangement Outstanding Securities
ShareBasedCompensationArrangementOutstandingSecurities
17589000 shares
CY2013Q4 snss Cash Equivalents Estimated Fair Value
CashEquivalentsEstimatedFairValue
6583000
CY2013Q4 snss Operating Leases Future Minimum Payments Effect Of Lease Extension Executed Due
OperatingLeasesFutureMinimumPaymentsEffectOfLeaseExtensionExecutedDue
446000
CY2013Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
2.56
CY2013Q4 snss Cash Equivalents Gross Unrealized Losses
CashEquivalentsGrossUnrealizedLosses
CY2013Q4 snss Operating Leases Future Minimum Payments Effect Of Lease Extension Executed Due In Two Years
OperatingLeasesFutureMinimumPaymentsEffectOfLeaseExtensionExecutedDueInTwoYears
114000
CY2013Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
5119000
CY2013Q4 snss Indemnification Liabilities Incurred
IndemnificationLiabilitiesIncurred
0
CY2013Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
2600000
CY2013Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
4750000
CY2013Q4 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675 pure
CY2013Q4 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
6583000
CY2013Q4 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
3099000 shares
CY2013Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
3000
CY2013Q4 snss Other Accruals Current
OtherAccrualsCurrent
133000
CY2013Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
6000
CY2013Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
1249000
CY2013Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
24175000
CY2013Q4 snss Office Space Leased Area
OfficeSpaceLeasedArea
15378 sqft
CY2013Q4 snss Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments
6000
CY2013Q4 snss Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
6000
CY2013Q4 snss Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
3000
CY2010Q4 snss Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
15500000
CY2010 snss Warrants Maturity Term
WarrantsMaturityTerm
P5Y
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46412000 shares
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22836000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14133000 shares
CY2011 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
CY2011 us-gaap Revenues
Revenues
5000000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
343000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20107000
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1400000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20141000
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
33000
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52082000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5984000
CY2011 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
371000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-20141000
CY2011 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-8549000
CY2011 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
371000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-25866000
CY2011 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2011 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
5878000
CY2011 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
34000
CY2011 us-gaap Interest Paid
InterestPaid
109000
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10300000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-20141000
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
68000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1369000
CY2011 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-244000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
CY2011 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
68000
CY2011 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
19000
CY2011 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
261000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8303000
CY2011 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
56000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13746000
CY2011 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
516000
CY2011 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
9625000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4912000
CY2011 us-gaap Interest Expense
InterestExpense
259000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
242000
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6848000
CY2011 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4178000
CY2011 snss License And Other Revenue
LicenseAndOtherRevenue
5000000
CY2011 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
4178000
CY2011 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
4053000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22563000
CY2011 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
294000
CY2011 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
125000
CY2013 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001061027
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-1995000
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1388000
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
56241000
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2011 us-gaap Operating Expenses
OperatingExpenses
30866000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
796000
CY2011 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
4053000
CY2013 dei Trading Symbol
TradingSymbol
SNSS
CY2013 dei Entity Registrant Name
EntityRegistrantName
SUNESIS PHARMACEUTICALS INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y9M18D
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.608 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.68
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52249000 shares
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.22
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2004000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.003 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37423000
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2013 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
577000 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M26D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M11D
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
104000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.39
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17589000 shares
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-31773000
CY2013 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
96000
CY2013 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-41000
CY2013 us-gaap Interest Paid
InterestPaid
2006000
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Significant Estimates and Judgments</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#x2019;s financial statements and notes thereto. Actual results could differ materially from these estimates. Significant estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting.</p> </div>
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
CY2013 us-gaap Revenues
Revenues
7956000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-489000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34639000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3400000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34598000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26894000
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7182000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4635000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29963000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
230000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-12458000
CY2013 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12600000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-34598000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
309000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3581000
CY2013 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
142000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
584000
CY2013 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
304000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
254000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10838000
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
621000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5388000
CY2013 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-76000
CY2013 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7956000
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
88000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
181000
CY2013 us-gaap Interest Expense
InterestExpense
2917000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
875000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11763000
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32216000
CY2013 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28891000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-16000
CY2013 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
0
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3885000
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59110000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2013 us-gaap Operating Expenses
OperatingExpenses
39729000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
2028000
CY2013 snss Number Of Tranches For Maximum Borrowing
NumberOfTranchesForMaximumBorrowing
2 Tranches
CY2013 snss Transfer Of Intrinsic Value Of Exercised Warrants To Additional Paid In Capital
TransferOfIntrinsicValueOfExercisedWarrantsToAdditionalPaidInCapital
43000
CY2013 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
371000
CY2013 snss Line Of Credit Facility Number Of Installments
LineOfCreditFacilityNumberOfInstallments
32 Installment
CY2013 snss License And Other Revenue
LicenseAndOtherRevenue
7956000
CY2013 snss Amended Operating Lease Expiration Date
AmendedOperatingLeaseExpirationDate
2015-04-30
CY2013 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P18M
CY2013 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
12357000
CY2013 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
11986000
CY2013 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2013 snss Operating Lease Expiration Date
OperatingLeaseExpirationDate
February 28, 2014
CY2013 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2013 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-699000
CY2013 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P9M
CY2013 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
11986000
CY2013 snss Line Of Credit Facility Final Payment
LineOfCreditFacilityFinalPayment
937500
CY2013 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
2704000
CY2012 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y9M18D
CY2012 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.787 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48146000 shares
CY2012 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.003 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10642000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16647000 shares
CY2012 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
CY2012 us-gaap Revenues
Revenues
3754000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
98000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43932000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2100000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43951000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
11000
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67608000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7490000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3893000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-43951000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
330000
CY2012 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-5351000
CY2012 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
770000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-34606000
CY2012 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2012 us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-7509000
CY2012 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
19000
CY2012 us-gaap Interest Paid
InterestPaid
1165000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13700000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-43951000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
172000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2402000
CY2012 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
82000
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1918000
CY2012 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
402000
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
322000
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
191000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9175000
CY2012 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37642000
CY2012 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
522000
CY2012 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
14982000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
19624000
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3130000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5629000
CY2012 us-gaap Interest Expense
InterestExpense
1855000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-580000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14943000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21371000
CY2012 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3122000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29185000
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
2570000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2724000
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46226000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2012 us-gaap Operating Expenses
OperatingExpenses
38360000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
350000
CY2012 snss Transfer Of Intrinsic Value Of Exercised Warrants To Additional Paid In Capital
TransferOfIntrinsicValueOfExercisedWarrantsToAdditionalPaidInCapital
1715000
CY2012 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
504000
CY2012 snss License And Other Revenue
LicenseAndOtherRevenue
3754000
CY2012 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
18124000
CY2012 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
17620000
CY2012 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
3079000
CY2012 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
17620000
CY2012 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
-6672000
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51587000 shares
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51587000 shares
CY2013Q1 us-gaap Revenues
Revenues
1989000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11624000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11624000
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46793000 shares
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46793000 shares
CY2012Q1 us-gaap Revenues
Revenues
0
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13924000
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13924000
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47286000 shares
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46953000 shares
CY2012Q2 us-gaap Revenues
Revenues
1500000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8579000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9332000
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53268000 shares
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51630000 shares
CY2013Q2 us-gaap Revenues
Revenues
1989000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8190000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9336000
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47398000 shares
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47398000 shares
CY2012Q3 us-gaap Revenues
Revenues
265000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17396000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17396000
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53271000 shares
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51698000 shares
CY2013Q3 us-gaap Revenues
Revenues
1989000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7607000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8329000
CY2012Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2012Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52848000 shares
CY2012Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2012Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51412000 shares
CY2012Q4 us-gaap Revenues
Revenues
1989000
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4052000
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10352000
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2013Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55573000 shares
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2013Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54060000 shares
CY2013Q4 us-gaap Revenues
Revenues
1989000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7177000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8257000

Files In Submission

Name View Source Status
0001193125-14-086649-index-headers.html Edgar Link pending
0001193125-14-086649-index.html Edgar Link pending
0001193125-14-086649.txt Edgar Link pending
0001193125-14-086649-xbrl.zip Edgar Link pending
d655022d10k.htm Edgar Link pending
d655022dex1044.htm Edgar Link pending
d655022dex1045.htm Edgar Link pending
d655022dex1046.htm Edgar Link pending
d655022dex1047.htm Edgar Link pending
d655022dex1048.htm Edgar Link pending
d655022dex1049.htm Edgar Link pending
d655022dex231.htm Edgar Link pending
d655022dex311.htm Edgar Link pending
d655022dex312.htm Edgar Link pending
d655022dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g655022g41v47.jpg Edgar Link pending
g655022g73u90.jpg Edgar Link pending
g655022image001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-20131231.xml Edgar Link completed
snss-20131231.xsd Edgar Link pending
snss-20131231_cal.xml Edgar Link unprocessable
snss-20131231_def.xml Edgar Link unprocessable
snss-20131231_lab.xml Edgar Link unprocessable
snss-20131231_pre.xml Edgar Link unprocessable